Tyra Biosciences
TYRA
49 hedge funds and large institutions have $314M invested in Tyra Biosciences in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
23% more capital invested
Capital invested by funds: $256M → $314M (+$58.2M)
2% more funds holding
Funds holding: 48 → 49 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
0.55% less ownership
Funds ownership: 85.6% → 85.04% (-0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$532K |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$451K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$277K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$202K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$440K |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$434K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$359K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$313K |
| 5 |
Janus Henderson Group
London,
|
-$277K |
TYRA Hedge Fund Activity: Q3 2022 in Review
49 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q3 2022, worth a combined $314M — up 23% from $256M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TYRA positions and 3 closed out — a net gain of 1 holder — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $532K. The largest seller was Woodline Partners, cutting an estimated $440K.
- 49 institutional investors held Tyra Biosciences (TYRA) as of Q3 2022, up from 48 in Q2 2022.
- Funds reported $314M of Tyra Biosciences stock for Q3 2022, up 23% quarter-over-quarter.
- 4 funds opened new Tyra Biosciences positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest Tyra Biosciences buyer in Q3 2022 was Fidelity Investments, an estimated $532K added.
- The largest Tyra Biosciences seller in Q3 2022 was Woodline Partners, an estimated $440K sold.
Based on aggregated 13F filings for Q3 2022.